Mepolizumab for eosinophilic COPD nork Sciurba, F, Bradford, E, Pavord, I

Mepolizumab for Eosinophilic Chronic Obstructive Pulmonary Disease (COPD): A Meta-Analysis of METREX and METREO Exacerbation Endpoints nork Bafadhel, M, Sciurba, F, Paggiaro, P, Pavord, I, Chapman, K, Yancey, S, Rubin, D, Mayer, B, Harris, S, Bradford, E

Mepolizumab for Eosinophilic Chronic Obstructive Pulmonary Disease (COPD): A Meta-Analysis of METREX and METREO Patient-Reported Outcomes, Response to Therapy and Lung Function nork Chapman, K, Pavord, I, Paggiaro, P, Sciurba, F, Bafadhel, M, Bradford, E, Harris, S, Mayer, B, Rubin, D, Yancey, S

Mepolizumab for eosinophilic chronic obstructive pulmonary disease nork Pavord, I, Chanez, P, Criner, G, Kerstjens, H, Korn, S, Lugogo, N, Martinot, J, Sagara, H, Albers, F, Bradford, E, Harris, S, Mayer, B, Rubin, D, Yancey, S, Sciurba, F

Benralizumab for the prevention of COPD exacerbations nork Criner, G, Celli, B, Brightling, C, Agusti, A, Papi, A, Singh, D, Sin, D, Vogelmeier, C, Sciurba, F, Bafadhel, M, Backer, V, Kato, M, Ramírez-Venegas, A, Wei, Y, Bjermer, L, Shih, V, Jison, M, O'Quinn, S, Makulova, N, Newbold, P, Goldman, M, Martin, U, Galathea and Terranova Study Investigators